Development Of An Endometrial Cancer Educational Tool
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT07739745
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Interactive Educational Website — OTHERParticipants will utilize website to access educational content, knowledge measure, values survey, and cognitive and usability testing
Study Details
The goal of this study is to develop an online educational tool that we can make widely available to broader patient community.
Key Dates
- First listed
- Jul 31, 2026
- Start date
- Jan 1, 2027
- Status verified
- Jul 2026
- Primary completion
- Jun 1, 2030
- Completion
- Jun 1, 2032
Study Design
- Enrollment
- 250 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Healthcare ProvidersHealthcare providers will be recruited from MD Anderson Cancer Center and outside institutions to reflect a broad group of physicians
- Experimental: PatientsParticipants will be recruited from the University of Texas MD Anderson Cancer Center (MDA), MDA Houston Area Locations (HALs), and The Harris Health System (LBJ).
Primary Outcome Measure
Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]
Central Contacts
- Larissa Meyer, MD, MPH(713) 745-0973
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT MD Anderson | Houston | Texas | 77030 | Larissa Meyer, MD, MPH (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By condition
By specialty
By research site
Related Studies
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPHASE1/PHASE2 · Recruiting · Novartis Pharmaceuticals · Atlanta, Georgia
- BP1001-A in Patients With Advanced or Recurrent Solid TumorsPHASE1 · Recruiting · Bio-Path Holdings, Inc. · Silver Spring, Maryland
- Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their DiseaseRecruiting · Memorial Sloan Kettering Cancer Center · Hartford, Connecticut